Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Pfizer, Merck trial antiviral combos amid concerns over resistance to COVID-19 pills

Summary by Ground News
FDA greenlighted Paxlovid and molnupiravir as the first oral COVID-19 therapies for at-home use last month. However, the mutations that allow viruses to evade the antivirals are a real danger for drugs. The researchers from Pfizer (PFE) and Merck (MRK) have rebuffed such fears noting that they did not see drug resistance during their trials.

1 Articles

Seeking AlphaSeeking Alpha
Lean Right

Pfizer, Merck trial antiviral combos amid concerns over resistance to COVID-19 pills

Pfizer (PFE) and Merck (MRK), the developers of the first oral medications for COVID-19 in the U.S., are advancing combination studies for their antiviral therapies as experts flag the...

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Saturday, January 22, 2022.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Pfizer icon

Pfizer

Merck icon

Merck

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal